Serum Oxytocin Levels in Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis and their Association with Disease Activity

ABSTRACT

Objectives Spondyloarthritis refers to a group of chronic inflammatory diseases that particularly involve the sacroiliac joints and spine but may also have an influence on extra-articular involvement in some patients. Oxytocin is a peptide hormone released from the hypothalamus and stored in the pituitary gland. It is known to have anti-inflammatory effects. The aim of this study was to investigate the serum levels of oxytocin and their potential association with disease activity and spinal mobility in patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nrAxSpA).

Material and Methods Seventy-one patients with nrAxSpA, 38 patients with AS and 67 healthy control subjects were included in this study. Disease activity was assessed by the Bath Ankylosing Spondylitis Disease Activity Index, and spinal mobility by the Bath Ankylosing Spondylitis Metrologic Index. Laboratory examinations included complete blood count, ESR, CRP and oxytocin tests.

Results There was no significant difference in serum levels of oxytocin among the 3 groups (p=0.973). However, serum levels of oxytocin correlated negatively with both ESR (r=− 0.359, p=0.027), CRP (r=− 0.316, p=0.056) and BASDAI scores (r=− 0,448, p=0.005) in patients with AS. On the other hand, serum levels of oxytocin had a negative correlation only with ESR in patients with nrAxSpA (r=− 0.321 p=0.009).Conclusion This study lays the foundation for further studies that may aim to investigate how addition of oxytocin to the treatment regimen impacts on disease activity in patients with AS who exhibit particularly low levels of oxytocin during the active disease period.

ZUSAMMENFASSUNG

Zielsetzung Spondylarthritiden sind chronisch entzündliche Erkrankungen, bei denen insbesondere die Iliosakralgelenke und die Wirbelsäule betroffen sind. Bei einigen Patienten besteht daneben auch eine extraartikuläre Manifestation. Oxytocin ist ein Peptidhormon, das aus dem Hypothalamus freigesetzt und in der Hypophyse gespeichert wird. Es ist bekannt, dass Oxytocin entzündungshemmende Wirkungen hat. Das Ziel dieser Studie war es, die Oxytocin-Serumspiegel und ihren möglichen Zusammenhang mit der Krankheitsaktivität, der Beweglichkeit der Wirbelsäule bei Patienten mit ankylosierender Spondylitis (AS) und nicht radiologischer axialer Spondyloathritis (nrAxSpA) zu untersuchen.

Patienten und Methoden 71 Patienten mit nrAxSpA und 38 Patienten mit AS sowie 67 gesunde Kontrollpersonen wurden in diese Studie eingeschlossen. Die Krankheitsaktivität wurde durch den Bath Ankylosing Spondylitis Disease Activity Index und die Wirbelsäulenmobilität durch den Bath Ankylosing Spondylitis Metrologic Index bewertet. Die Laboruntersuchungen umfassten vollständige Blutbild-, ESR-, CRP- und Oxytocin-Tests.

Ergebnisse Es gab keinen signifikanten Unterschied in den Serumspiegeln von Oxytocin zwischen den drei Gruppen (p = 0,973). Die Serumspiegel von Oxytocin korrelierten jedoch sowohl mit ESR- (r = − 0,359, p = 0,027) als auch CRP-(r = − 0,316, p = 0,056) und BASDAI-Werten (r = − 0,448, p = 0,005) bei Patienten mit AS negativ . Andererseits hatten die Oxytocin-Serumspiegel nur bei den Patienten mit nrAxSpA eine negative Korrelation mit der ESR (r = − 0,321 p = 0,009).

Schlussfolgerung Diese Studie bildet die Grundlage für weitere Studien, die untersuchen sollen, wie sich die Zugabe von Oxytocin zum Behandlungsschema auf die Krankheitsaktivität bei Patienten mit AS auswirkt, die während der aktiven Krankheitsperiode besonders niedrige Oxytocinspiegel aufweisen.

Key words

ankylosing spondylitis - non-radiographic axial spondyloarthritis - disease activity - oxytocin

Schlüsselwörter

Spondylitis ankylosans - nicht radiologische axiale Spondyloarthritis - Oxytocin - Krankheitsaktivität

Publication History

Article published online:
27 January 2021

• References

• 1 Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 390: 73-84
• 2 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368
• 3 Rudwaleit M, van der Heijde D, Landewé R. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-783
• 4 Kiss A, Mikkelsen JD. Oxytocin – anatomy and functional assignments: a minireview. Endocr Regul 2005; 39: 97-105
• 5 Iseri SO, Sener G, Saglam B. et al. Oxytocin protects against sepsis-induced multiple organ damage: Role of neutrophils. J Surg Res 2005; 126: 73-81
• 6 Dusunceli F, Iseri SO, Ercan F. et al. Oxytocin alleviates hepatic ischemia-reperfusion injury in rats. Peptides 2008; 29: 1216-1222
• 7 Clodi M, Vila G, Geyeregger R. et al. Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab 2008; 295: 686-691
• 8 Garrett S, Jenkinson T, Kennedy LG. et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994; 21: 2286Y2291
• 9 Akkoc Y, Karatepe AG, Akar S. et al. A Turkish version of the Bath ankylosing spondylitis disease activity index: reliability and validity. Rheumatol Int 2005; 25: 280Y284
• 10 Jenkinson TR, Mallorie P, Whitelock HC. et al Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrological Index (BASMI). J Rheumatol 1994; 21: 1694-1698
• 11 Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol 1998; 156: 223-229
• 12 Wu Y, Wu T, Xu B. et al. Oxytocin prevents cartilage matrix destruction via regulating matrix metalloproteinases. Biochem Biophys Res Commun 2017; 6 486: 601-606
• 13 West HF. Aetiology of ankylosing spondylitis. Ann Rheum Dis 1949; 8: 143-148
• 14 Polley HF, Slocumb CH. Rheumatoid spondylitis; a study of 1035 cases. Ann Rheum Dis 1947; 6: 95-98
• 15 Moll JM, Haslock I, Macrae IF. et al. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore) 1974; 53: 343-364
• 16 van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. Nat Rev Rheumatol 2015; 11: 110-118
• 17 Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev Rheumatol 2012; 8: 262-268
• 18 Slobodin G, Reyhan I, Avshovich N. et al. Recently diagnosed axial spondyloarthritis: gender differences and factors related to delay in diagnosis. Clin Rheumatol 2011; 30: 1075-1080
• 19 Lin Z, Xu H, Gu J. et al. Investigation and analysis on the delayed diagnosis in patients with ankylosing spondylitis in a Chinese population. Clin Exp Rheumatol 2008; 26: 1163
• 20 Feldtkeller E, Khan MA, van der Heijde D. et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23: 61-66
• 21 Nakashima Y, Ohishi M, Okazaki K. et al. Delayed diagnosis of ankylosing spondylitis in a Japanese population. Mod Rheumatol 2016; 26: 421-425
• 22 Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999; 26: 966-970
• 23 Bal A, Unlu E, Bahar G. et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007; 26: 211-215
• 24 Szeto DA, Nation AJ, Mendez J. et al. Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab; 2008; 295: E1495-E1501
• 25 Yuan L, Liu S, Bai X. et al. Oxytocin inhibits lipopolysaccharide-induced inflammation in microglial cells and attenuates microglial activation in lipopolysaccharide-treated mice. J Neuroinflammation 2016; 13: 77
• 26 Tang Y, Shi Y, Gao Y. et al. Oxytocin system alleviates intestinal inflammation by regulating macrophages polarization in experimental colitis. Clin Sci (Lond) 2019; 133: 1977-1992
• 27 Garrido-Urbani S, Deblon N, Poher AL. et al. Inhibitory role of oxytocin on TNF_ expression assessed in vitro and in vivo. Diabetes Metab 2018; 44: 292-295
• 28 Biyikli NK, Tugtepe H, Sener G. et al. Oxytocin alleviates oxidative renal injury in pyelonephritic rats via a neutrophil-dependent mechanism. Peptides 2006; 27: 2249-2257
• 29 Iseri SO, Sener G, Saglam B. et al. Oxytocin ameliorates oxidative colonic inflammation by a neutrophil-dependent mechanism. Peptides 2005; 26: 483-491
• 30 Petersson M, Lundeberg T, Sohlstrom A. et al. Oxytocin increases the survival of musculocutaneous flaps. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 701-704
• 31 Petersson M, Wiberg U, Lundeberg T. et al. Oxytocin decreases carrageenan induced inflammation in rats. Peptides 2001; 22: 1479-1484
• 32 Elands J, Resink A, de Kloet ER. Neurohypophyseal hormone receptors in the rat thymus, spleen, and lymphocytes. Endocrinology. 1990; 126: 2703-2710
• 33 Schmid B, Wong S, Mitchell BF. Transcriptional regulation of oxytocin receptor by interleukin-1beta and interleukin-6. Endocrinology 2001; 142: 1380-1385
• 34 Jankowski M, Bissonauth V, Gao L. et al Anti-inflammatory effect of oxytocin in rat myocardial infarction. Basic Res Cardiol 2010; 105: 205-218
• 35 Anderberg UM, Uvnas-Moberg K. Plasma oxytocin levels in female fibromyalgia syndrome patients. Z Rheumatol 2000; 59: 373-379
• 36 Miwa Y, Furuya H, Yanai R. et al. The Relationship between the Serum Oxytocin Levels, Disease Activity, the ADLs and the QOL in Patients with Rheumatoid Arthritis. Intern Med 2017; 56: 3167-3172
• 37 Kutake Y, Imamura Y, Mizogushi Y. et al. In female mild cognitive impairment and Alzheimer type dementia, peripheral oxytocin concentration is lower than healthy elderly. Jpn J Psychiatr Neurol 2016; 528
• 38 Welch MG, Margolis KG, Li Z. et al. Oxytocin regulates gastrointestinal motility, inflammation, macromolecular permeability, and mucosal maintenance in mice. Am J Physiol Gastrointest Liver Physiol 2014; 307: G848-G862
• 39 Van Praet L, Van den Bosch FE, Jacques P. et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013; 72: 414-417
• 40 Mielants H, Veys EM, Cuvelier C. et al. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol 1988; 27: 95-105
• 41 Imami AS, O’Donovan SM, Creeden JF. et al. Oxytocin’s anti-inflammatory and proimmune functions in COVID-19: a transciptomic signature based approach. Physiol Genomics 2020; 52: 401-407